# Phase 2 Lymphoma, Large B-Cell, Diffuse trials: 108 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 108 trials in phase 2 for Lymphoma, Large B-Cell, Diffuse that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lymphoma, Large B-Cell, Diffuse trials: 108 rows for $5.40, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma-large-b-cell-diffuse

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 108
- Recruiting or not yet: 108
- Read on: November 19, 2026

## Trials

The 25 newest of 108, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939685 | Entinostat + R-CHOP in Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL: Phase II Trial | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939685) |
| November 16, 2026 | NCT07938619 | Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938619) |
| November 4, 2026 | NCT07917624 | Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917624) |
| October 23, 2026 | NCT07892027 | Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma... | University of Michigan Rogel Cancer Center | Phase 2 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma... | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892027) |
| October 15, 2026 | NCT07875413 | Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875413) |
| September 10, 2026 | NCT07814001 | Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy | The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814001) |
| August 19, 2026 | NCT07774234 | Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774234) |
| August 13, 2026 | NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Recruiting | Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell... | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763210) |
| August 5, 2026 | NCT07748364 | Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748364) |
| July 20, 2026 | NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Kure Cells, INC | Phase 2 | Not yet recruiting | Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713459) |
| July 14, 2026 | NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After... | Yonsei University | Phase 2 | Not yet recruiting | Diffuse Large B-cell Lymphoma | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702851) |
| June 17, 2026 | NCT07654426 | The CARDIOPROTECT Trial | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654426) |
| June 8, 2026 | NCT07634289 | Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma | Olivia Newton-John Cancer Research Institute | Phase 2 | Not yet recruiting | Relapsed /Refractory DLBCL | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634289) |
| May 27, 2026 | NCT07608978 | Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608978) |
| May 20, 2026 | NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599423) |
| May 15, 2026 | NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588698) |
| April 13, 2026 | NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell... | Beijing Tongren Hospital | Phase 2 | Recruiting | Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523737) |
| April 8, 2026 | NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | University of Nebraska | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517705) |
| April 2, 2026 | NCT07507318 | Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission | Sponsor not shown (see the record) | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507318) |
| March 31, 2026 | NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | Brown University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502872) |
| March 30, 2026 | NCT07499271 | Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499271) |
| March 27, 2026 | NCT07494565 | Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL | Sun Yat-sen University | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494565) |
| March 25, 2026 | NCT07493148 | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL | Sponsor not shown (see the record) | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493148) |
| March 24, 2026 | NCT07489989 | Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. | Sponsor not shown (see the record) | Phase 2 | Recruiting | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489989) |
| March 5, 2026 | NCT07451652 | Low Dose Epcoritamab Plus GemOx in R/R DLBCL | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 | Recruiting | Relapsed/Refractory Diffuse Large B Cell Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451652) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 6 |
| Sun Yat-sen University | 5 |
| The First Affiliated Hospital of Soochow University | 4 |
| City of Hope Medical Center | 3 |
| The First Affiliated Hospital with Nanjing Medical University | 3 |
| Beijing Tongren Hospital | 3 |
| Navy General Hospital, Beijing | 3 |
| Mayo Clinic | 2 |
| University of Washington | 2 |
| National Cancer Institute (NCI) | 2 |
| Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2 |
| Fudan University | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 2 |
| First Affiliated Hospital of Ningbo University | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| University of California, Davis | 2 |
| SWOG Cancer Research Network | 2 |
| Medical College of Wisconsin | 1 |
| Kure Cells, INC | 1 |
| Vastra Gotaland Region | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Shanghai Zhongshan Hospital | 1 |
| The Lymphoma Academic Research Organisation | 1 |
| The First Affiliated Hospital of Xiamen University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 45 |
| China | 40 |
| Canada | 5 |
| Spain | 4 |
| France | 4 |
| Italy | 4 |
| Australia | 4 |
| South Korea | 4 |
| Germany | 4 |
| Poland | 3 |
| Belgium | 2 |
| Hungary | 2 |
| New Zealand | 2 |
| Sweden | 1 |
| Austria | 1 |
| Croatia | 1 |
| Czechia | 1 |
| Finland | 1 |
| Netherlands | 1 |
| Portugal | 1 |
| Turkey (Türkiye) | 1 |
| Brazil | 1 |
| Puerto Rico | 1 |
| Taiwan | 1 |
| Ireland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Payroll companies in the United States](https://specstream.ai/data/businesses/payroll-companies/united-states)
- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
- [Gastropubs in the United States](https://specstream.ai/data/businesses/gastropubs/united-states)
- [Real estate investment firms in the United States](https://specstream.ai/data/businesses/real-estate-investment-firms/united-states)
